Drugs Graham Net Net from 2010 to 2026

DMAA Stock   10.43  0.01  0.1%   
Drugs Made's Graham Net Net is decreasing over the years with slightly volatile fluctuation. Graham Net Net is expected to dwindle to 0.000052. From 2010 to 2026 Drugs Made Graham Net Net quarterly data regression line had arithmetic mean of  0.000064 and r-squared of  0.29. View All Fundamentals
 
Graham Net Net  
First Reported
2010-12-31
Previous Quarter
0.000058
Current Value
0.000052
Quarterly Volatility
0.00000342
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Drugs Made financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Drugs Made's main balance sheet or income statement drivers, such as , as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Drugs financial statements analysis is a perfect complement when working with Drugs Made Valuation or Volatility modules.
Check out the analysis of Drugs Made Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Drugs Made In is a strong investment it is important to analyze Drugs Made's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Drugs Made's future performance. For an informed investment choice regarding Drugs Stock, refer to the following important reports:
Check out the analysis of Drugs Made Correlation against competitors.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Diversified Capital Markets space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Drugs Made assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Drugs Made In is measured differently than its book value, which is the value of Drugs that is recorded on the company's balance sheet. Investors also form their own opinion of Drugs Made's value that differs from its market value or its book value, called intrinsic value, which is Drugs Made's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Drugs Made's market value can be influenced by many factors that don't directly affect Drugs Made's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Drugs Made's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.